Cambridge Heart Announces Third Quarter Results.

BEDFORD, Mass.--(BW HealthWire)--Nov. 5, 1997--Cambridge Heart, Inc. (NASDAQ:CAMH) today reported revenues of $340,000 for the quarter ended September 30, 1997, compared with revenue of $235,000 a year ago. Net loss for the third quarter of 1997 was ($1,249,000) or ($0.12) per share, compared to a loss of ($1,061,000) or ($0.11) per share on a proforma basis, for the same period last year.

Management noted that revenue for the quarter remains modest reflecting our targeted approach to distribution pending expansion of our labeling claims and the publication of additional clinical data.

"Our strategy for commercialization of our CH 2000 system continues to have three key elements, as reflected in our third quarter activities and financial performance," noted Jeffrey M. Arnold, Cambridge Heart Chairman, President, and Chief Executive Officer.

"First, we are building a strong foundation of published clinical data to prove the predictive value of our T-wave alternans in identifying patients at risk for ventricular arrhythmias. Our clinical study for expanding our labeling claim is on track for completion during the first half of 1998 and we have seen the recent publication of additional scientific papers supporting the clinical efficacy of our technology.

"Second, we are building a strong international base of reference sites which we call Centers of Excellence, and then using these reference sites to assist in educating the broader cardiology community about the benefits of our technology. Through these Centers, we are regularly supporting educational symposia on T-wave alternans such as that recently sponsored by Columbia University in New York and others recently held in Europe and Japan. We are supporting the upcoming program, "Recent Advances in T-Wave Alternans," sponsored by Case Western Reserve University School of Medicine and being held as a satellite symposium at the American Heart Association Annual Scientific Sessions in Orlando this coming weekend.

"Third, we are building a worldwide distribution system to enable us to fulfill the market potential for our products once we receive labeling approval and see the publication of additional clinical data. We have established an initial network in the United States, Europe, and the Far East, and plan to modify and broaden this capability in the months ahead," Mr. Arnold added.

Cambridge Heart is engaged in the research, development, and commercialization of products for the noninvasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac death, the early detection of coronary artery disease, and the prompt and accurate diagnosis of heart attack.

-0-

Statements made in this news release that are not historical facts include forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are included in Cambridge Heart's Annual Report on Form 10-K for the year ending December 31, 1996.

                           Cambridge Heart, Inc.
                           Financial Highlights

                          Three months              Nine months
Statement                     ended                    ended
of Operations             September 30,             September 30,
                        1997         1996         1997         1996

Revenues             $340,179     $235,305    $1,077,658     $500,007
Cost of
  goods sold          331,528      246,416       969,245      553,747
Expenses
  Research and
    development       757,814      628,105     2,786,755    1,514,437
  Selling,
    general and
    administrative    742,622      580,023     2,466,643    1,383,610
Loss from
  operations       (1,491,785)  (1,219,239)   (5,144,985)  (2,951,787)
Interest income       242,525      158,192       707,878      238,506
Net loss          ($1,249,260) ($1,061,047)  ($4,437,107) ($2,713,281)

Pro forma loss
  per share            ($0.12)      ($0.11)       ($0.43)      ($.32)

Pro forma
  weighted
  average
  shares           10,495,282    9,300,478    10,406,818    8,501,685

-0-

Condensed
Balance Sheet     September 30, December 31,
                      1997          1996
                  (unaudited)
Assets
  Current assets
    Cash and cash
      equivalents  $7,854,315  $18,588,583
    Marketable
      securities    6,569,271           --
    Accounts
      receivable      460,500      420,984
    Inventory         274,848      251,788
    Prepaid/other
      current assets  269,967      384,422
  Total current
    assets         15,428,901   19,645,777
  Fixed assets, net   632,604      423,159
  Other assets        107,373      160,523
                  $16,168,878  $20,229,459

Liabilities and stockholders' equity
  Accounts payable/
  accrued expenses   $474,214     $499,721

Stockholders' equity
    Common stock       10,550       10,215
    Additional
    paid in
      capital      29,285,031   29,216,646
    Accumulated
      deficit     (13,552,792)  (9,115,685)
    Less deferred
      compensation    (48,125)    (381,438)
Total stockholders'
  equity           15,694,664   19,729,738
                  $16,168,878  $20,229,459

     The Company intends to file its quarterly report on Form 10-Q
with the Securities and Exchange Commission shortly. Interested
parties are encouraged to review this report.

CONTACT: Cambridge Heart, Inc

Evanthia Malliris, 781/271-1200